Status:
UNKNOWN
Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborating Sponsors:
Zhejiang University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Effects of Chemotherapy
Stage IVC Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcino...
Detailed Description
To evaluate the progression free survival (PFS), overall survival (OS), Acute adverse reaction of recombinant human endostatin (endostar) combined with chemotherapy to the metastatic nasopharyngeal ca...
Eligibility Criteria
Inclusion
- metastatic nasopharyngeal carcinoma 6 months after first treatment,never receive any anticancer treatment except local radiotherapy to the bone metastasis，at least one measurable metastatic lesions，ECOG PS 0-1，Electrocardiogram (ecg) no special abnormal，comply with the test requirements, cooperate with regular follow-up.
Exclusion
- To give local treatment,clinical severe infection(\>grade 2),with the central nervous system metastases,ECOG PS≥2,patients with pregnancy or breastfeeding,has a history of peripheral nerve disease,concomitant with other serious diseases,ever or concomitant with other serious diseases except for Cervical carcinoma in situ,cure of basal cell carcinoma,bladder surface tumor,any cancer 3 years after curation.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
362 Patients enrolled
Trial Details
Trial ID
NCT01915134
Start Date
August 1 2013
End Date
December 1 2016
Last Update
January 1 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022